Home » Stocks » RETA

Reata Pharmaceuticals, Inc. (RETA)

Stock Price: $116.99 USD -0.16 (-0.14%)
Updated Jan 26, 2021 3:57 PM EST - Market open
Market Cap 4.09B
Revenue (ttm) 8.50M
Net Income (ttm) -368.92M
Shares Out 33.71M
EPS (ttm) -11.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $116.99
Previous Close $117.15
Change ($) -0.16
Change (%) -0.14%
Day's Open 118.81
Day's Range 115.88 - 118.81
Day's Volume 243,035
52-Week Range 93.53 - 247.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...

PRNewsWire - 1 month ago

NEW YORK, Dec. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in th...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwee...

Newsfile Corp - 1 month ago

Los Angeles, California--(Newsfile Corp. - December 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 10, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA...

Newsfile Corp - 1 month ago

Los Angeles, California--(Newsfile Corp. - December 10, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reat...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--DEADLINE MONDAY ALERT: The Schall Law Firm Announces it is Investigating Claims Against Reata Pharmaceuticals, Inc.

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 9, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities ...

Newsfile Corp - 1 month ago

Los Angeles, California--(Newsfile Corp. - December 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata ...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the ...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (...

Newsfile Corp - 1 month ago

Los Angeles, California--(Newsfile Corp. - December 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata ...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...

Newsfile Corp - 1 month ago

Los Angeles, California--(Newsfile Corp. - December 7, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata...

GlobeNewsWire - 1 month ago

PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing o...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwee...

GlobeNewsWire - 1 month ago

PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has p...

GlobeNewsWire - 1 month ago

PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of...

PRNewsWire - 1 month ago

NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action that h...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - November 29, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action t...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) and...

Zacks Investment Research - 2 months ago

Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...

GlobeNewsWire - 2 months ago

PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that t...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata...

PRNewsWire - 2 months ago

NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 13, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 11, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities...

Seeking Alpha - 2 months ago

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q3 2020 Results - Earnings Call Transcript

Insider Monkey - 2 months ago

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel ...

Benzinga - 2 months ago

Shares of Reata Pharmaceuticals (NASDAQ:RETA) rose 17.5% in pre-market trading after the company reported Q3 results.

GlobeNewsWire - 2 months ago

BARDOXOLONE ACHIEVED THE YEAR 2 PRIMARY AND KEY SECONDARY ENDPOINT S WITH STATISTICALLY SIGNIFICANT IMPROVEMENT S IN EGFR AS COMPARED TO PLACEBO AT WEEK 100 AND WEEK 104

GlobeNewsWire - 2 months ago

REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME

PRNewsWire - 2 months ago

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15,...

GlobeNewsWire - 2 months ago

PLANO, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that i...

PRNewsWire - 2 months ago

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and cer...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - October 30, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and Au...

GlobeNewsWire - 2 months ago

PLANO, Texas, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that r...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and Au...

PRNewsWire - 3 months ago

NEW YORK, Oct. 23, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pha...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASD...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Reata Pharmaceuticals, Inc. (NA...

GuruFocus - 3 months ago

Smaller biotechs would make nice additions to pharma companies in similar areas of therapy

Other stocks mentioned: IOVA, GBT
Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 21, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the secur...

About RETA

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone th... [Read more...]

Industry
Biotechnology
IPO Date
May 26, 2016
CEO
J. Warren Huff
Employees
220
Stock Exchange
NASDAQ
Ticker Symbol
RETA
Full Company Profile

Financial Performance

In 2019, RETA's revenue was $26.52 million, a decrease of -50.52% compared to the previous year's $53.59 million. Losses were -$290.17 million, 260.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for RETA stock is "Strong Buy." The 12-month stock price forecast is 246.75, which is an increase of 110.92% from the latest price.

Price Target
$246.75
(110.92% upside)
Analyst Consensus: Strong Buy